abrdn Healthcare Opportunities Fund Q2 2026 Commentary

The equity portion of the abrdn Healthcare Opportunities Fund gained (gross of fees) and outperformed its benchmark. uniQure was the standout contributor as its shares re-rated dramatically after the FDA agreed that the three-year AMT-130 (gene therapy) data set in Huntington's disease could serve as the primary basis for a BLA under accelerated approval. Boston Scientific was among the largest detractors, weighed down by slower uptake of Watchman (device), faster-than-expected market share loss in electrophysiology and a reduced growth outlook.